267 related articles for article (PubMed ID: 11443562)
41. Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation.
Balassa K; Salisbury R; Watson E; Lubowiecki M; Tseu B; Maouche N; Jeffery K; Misbah SA; Benamore R; Rowley L; Barton D; Pawson R; Danby R; Rocha V; Peniket A
J Infect; 2019 Jun; 78(6):461-467. PubMed ID: 30965067
[TBL] [Abstract][Full Text] [Related]
42. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature.
Khanna N; Widmer AF; Decker M; Steffen I; Halter J; Heim D; Weisser M; Gratwohl A; Fluckiger U; Hirsch HH
Clin Infect Dis; 2008 Feb; 46(3):402-12. PubMed ID: 18181739
[TBL] [Abstract][Full Text] [Related]
43. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
44. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.
Pollack P; Groothuis JR
J Infect Chemother; 2002 Sep; 8(3):201-6. PubMed ID: 12373481
[TBL] [Abstract][Full Text] [Related]
45. Palivizumab.
Scott LJ; Lamb HM
Drugs; 1999 Aug; 58(2):305-11; discussion 312-3. PubMed ID: 10473022
[TBL] [Abstract][Full Text] [Related]
46. Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis.
Robbins JM; Tilford JM; Gillaspy SR; Shaw JL; Simpson DD; Jacobs RF; Wheeler JG
Ambul Pediatr; 2002; 2(6):444-8. PubMed ID: 12437390
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
48. Respiratory syncytial virus: different criteria for palivizumab use in different areas?
Mitchell I
South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741
[No Abstract] [Full Text] [Related]
49. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
50. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan.
Mori M; Kawashima H; Nakamura H; Nakagawa M; Kusuda S; Saji T; Tsutsumi H; Yokota S; Itoh S;
J Infect Chemother; 2011 Apr; 17(2):254-63. PubMed ID: 20872156
[TBL] [Abstract][Full Text] [Related]
51. A multicenter investigation of respiratory syncytial viral infection in children with hematopoietic cell transplantation.
Rowan CM; Gertz SJ; Zinter MS; Moffet J; Bajwa RPS; Barnum JL; Kong M;
Transpl Infect Dis; 2018 Jun; 20(3):e12882. PubMed ID: 29573141
[TBL] [Abstract][Full Text] [Related]
52. Palivizumab: where to from here?
Georgescu G; Chemaly RF
Expert Opin Biol Ther; 2009 Jan; 9(1):139-47. PubMed ID: 19063700
[TBL] [Abstract][Full Text] [Related]
53. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients.
Hynicka LM; Ensor CR
Ann Pharmacother; 2012 Apr; 46(4):558-66. PubMed ID: 22395247
[TBL] [Abstract][Full Text] [Related]
54. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
[TBL] [Abstract][Full Text] [Related]
55. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
56. Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT.
Anak S; Atay D; Unuvar A; Garipardic M; Agaoglu L; Ozturk G; Karakas Z; Devecioglu O
Pediatr Pulmonol; 2010 Mar; 45(3):307-11. PubMed ID: 20146398
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease.
Saji T; Nakazawa M; Harada K
Pediatr Int; 2005 Aug; 47(4):397-403. PubMed ID: 16091076
[TBL] [Abstract][Full Text] [Related]
58. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model.
Saadah LM; Chedid FD; Sohail MR; Nazzal YM; Al Kaabi MR; Rahmani AY
Pharmacotherapy; 2014 Mar; 34(3):251-9. PubMed ID: 23897635
[TBL] [Abstract][Full Text] [Related]
59. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.
Ottolini MG; Curtis SR; Mathews A; Ottolini SR; Prince GA
Bone Marrow Transplant; 2002 Jan; 29(2):117-20. PubMed ID: 11850705
[TBL] [Abstract][Full Text] [Related]
60. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
Zhu Q; McAuliffe JM; Patel NK; Palmer-Hill FJ; Yang CF; Liang B; Su L; Zhu W; Wachter L; Wilson S; MacGill RS; Krishnan S; McCarthy MP; Losonsky GA; Suzich JA
J Infect Dis; 2011 Mar; 203(5):674-82. PubMed ID: 21208913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
